Acute Myeloid Leukemia is the deadliest form of leukemia that affects mostly people over 60 years of age.  API’s most advanced product candidate is indicated for AML in adults 60 years and older.  Of those, 64% do not receive any treatment other than supportive.  The Company believes that upon continued demonstration of the current safety profile of the drug candidate its target indication can be expanded to include all elderly patients with newly diagnosed AML.  

Other indications in which a significant amount of preclinical and/or related clinical work has been completed include: bone marrow ablation in preparation for bone marrow transplantation, metastatic colorectal cancer, metastatic prostate cancer and antiangiogenesis (targeting blood supply to any solid cancer).